<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39366988</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Exploring the ability of the MD+FoldX method to predict SARS-CoV-2 antibody escape mutations using large-scale data.</ArticleTitle><Pagination><StartPage>23122</StartPage><MedlinePgn>23122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-72491-z</ELocationID><Abstract><AbstractText>Antibody escape mutations pose a significant challenge to the effectiveness of vaccines and antibody-based therapies. The ability to predict these escape mutations with computer simulations would allow us to detect threats early and develop effective countermeasures, but a lack of large-scale experimental data has hampered the validation of these calculations. In this study, we evaluate the ability of the MD+FoldX molecular modeling method to predict escape mutations by leveraging a large deep mutational scanning dataset, focusing on the SARS-CoV-2 receptor binding domain. Our results show a positive correlation between predicted and experimental data, indicating that mutations with reduced predicted binding affinity correlate moderately with higher experimental escape fractions. We also demonstrate that higher precision can be achieved using affinity cutoffs tailored to distinct SARS-CoV-2 antibodies from four different classes rather than a one-size-fits-all approach. Further, we suggest that the quartile values of optimized cutoffs reported for each class in this study can serve as a valuable guide for future work on escape mutation predictions. We find that 70% of the systems surpass the 50% precision mark, and demonstrate success in identifying mutations present in significant variants of concern and variants of interest. Despite promising results for some systems, our study highlights the challenges in comparing predicted and experimental values. It also emphasizes the need for new binding affinity methods with improved accuracy that are fast enough to estimate hundreds to thousands of antibody-antigen binding affinities.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>L América</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Institute for Modeling Collaboration and Innovation, University of Idaho, Moscow, ID, 83844, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Jonathan E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Institute for Modeling Collaboration and Innovation, University of Idaho, Moscow, ID, 83844, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Jagdish Suresh</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Institute for Modeling Collaboration and Innovation, University of Idaho, Moscow, ID, 83844, USA. jspatel@uidaho.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Biological Engineering, University of Idaho, Moscow, ID, 83844, USA. jspatel@uidaho.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ytreberg</LastName><ForeName>F Marty</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Institute for Modeling Collaboration and Innovation, University of Idaho, Moscow, ID, 83844, USA. ytreberg@uidaho.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physics, University of Idaho, Moscow, ID, 83844, USA. ytreberg@uidaho.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM104420</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20GM104420</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2024 May 22:2024.05.22.595230. doi: 10.1101/2024.05.22.595230</RefSource><PMID Version="1">38826284</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody</Keyword><Keyword MajorTopicYN="N">DMS</Keyword><Keyword MajorTopicYN="N">Escape mutation</Keyword><Keyword MajorTopicYN="N">FoldX</Keyword><Keyword MajorTopicYN="N">MD</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39366988</ArticleId><ArticleId IdType="pmc">PMC11452645</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-72491-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-72491-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boggiano, C. et al. Update on and future directions for use of anti-sars-cov-2 antibodies: National institutes of health summit on treatment and prevention of covid-19. Ann. Intern. Med.175, 119–126 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8559823</ArticleId><ArticleId IdType="pubmed">34724404</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar, G., Zhang, N., Fu, T.-M. &amp; An, Z. Antibody therapies for the prevention and treatment of viral infections. npj Vaccines2, 19 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5627241</ArticleId><ArticleId IdType="pubmed">29263875</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam, E. H., Peng, Y., Cheah, M. X. Y., Yan, C. &amp; Xiao, T. Neutralizing antibodies to block viral entry and for identification of entry inhibitors. Antiviral Res.1, 105834 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38369246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahangarzadeh, S. et al. An update on antiviral antibody-based biopharmaceuticals. Int. Immunopharmacol.86, 106760 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336121</ArticleId><ArticleId IdType="pubmed">32645633</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton, D. R. Antiviral neutralizing antibodies: From in vitro to in vivo activity. Nat. Rev. Immunol23, 720–734 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10108814</ArticleId><ArticleId IdType="pubmed">37069260</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Q., Han, X. &amp; Yan, J. Structure-based neutralizing mechanisms for sars-cov-2 antibodies. Emerg. Microbes Infect.11, 2412–2422 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9553185</ArticleId><ArticleId IdType="pubmed">36106670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner, T. R. et al. Neutrobodyplex-monitoring sars-cov-2 neutralizing immune responses using nanobodies. EMBO Rep.22, e52325 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8097376</ArticleId><ArticleId IdType="pubmed">33904225</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcami, A. &amp; Koszinowski, U. H. Viral mechanisms of immune evasion. Immunol. Today21, 447–455 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141567</ArticleId><ArticleId IdType="pubmed">10953097</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli, A. M. et al. Sars-cov-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol.21, 162–177 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossen, M. T., Westerhout, E. M., Söderberg-Nauclér, C. &amp; Wiertz, E. J. Viral immune evasion: A masterpiece of evolution. Immunogenetics54, 527–542 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12439615</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes, C. O. et al. Sars-cov-2 neutralizing antibody structures inform therapeutic strategies. Nature588, 682–687 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y. et al. Broadly neutralizing antibodies to sars-cov-2 and other human coronaviruses. Nat. Rev. Immunol.23, 189–199 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney, A. J. et al. Complete mapping of mutations to the sars-cov-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe29, 44–57 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong, J. et al. Genetic and structural basis for sars-cov-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol.6, 1233–1244 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8543371</ArticleId><ArticleId IdType="pubmed">34548634</ArticleId></ArticleIdList></Reference><Reference><Citation>Francino-Urdaniz, I. M. et al. One-shot identification of sars-cov-2 s rbd escape mutants using yeast screening. Cell Rep.36, 1 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352667</ArticleId><ArticleId IdType="pubmed">34416153</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasello, G., Armenia, I. &amp; Molla, G. The protein imager: A full-featured online molecular viewer interface with server-side hq-rendering capabilities. Bioinformatics36, 2909–2911 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31930403</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong, W. et al. Sabres: In silico detection of drug resistance conferring mutations in subpopulations of sars-cov-2 genomes. BMC Infect. Dis.23, 303 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10165565</ArticleId><ArticleId IdType="pubmed">37158832</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha, G. et al. Priest-predicting viral mutations with immune escape capability of sars-cov-2 using temporal evolutionary information. BioRxiv1, 1 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11091746</ArticleId><ArticleId IdType="pubmed">38742520</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, S.-H. et al. In silico prediction of immune-escaping hot spots for future covid-19 vaccine design. Sci. Rep.13, 13468 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10439115</ArticleId><ArticleId IdType="pubmed">37596329</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai, K.-C., Lee, Y.-C. &amp; Tseng, T.-S. Comprehensive deep mutational scanning reveals the immune-escaping hotspots of sars-cov-2 receptor-binding domain targeting neutralizing antibodies. Front. Microbiol.12, 698365 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319916</ArticleId><ArticleId IdType="pubmed">34335530</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes, J. E., Lund-Andersen, P. K., Patel, J. S. &amp; Ytreberg, F. M. The effect of mutations on binding interactions between the sars-cov-2 receptor binding domain and neutralizing antibodies b38 and cb6. Sci. Rep.12, 18819 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9637166</ArticleId><ArticleId IdType="pubmed">36335244</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurya, S., Kumar, S. &amp; Padhi, A. K. Interface-guided computational protein design reveals bebtelovimab-resistance mutations in sars-cov-2 rbd: Correlation with global viral genomes and bebtelovimab-escape mutations. ChemistrySelect8, e202302906 (2023).</Citation></Reference><Reference><Citation>Thadani, N. N. et al. Learning from prepandemic data to forecast viral escape. Nature1, 1–8 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10599991</ArticleId><ArticleId IdType="pubmed">37821700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostolansky, F. et al. The strong positive correlation between effective affinity and infectivity neutralization of highly cross-reactive monoclonal antibody iib4, which recognizes antigenic site b on influenza a virus haemagglutinin. J. Gen. Virol.81, 1727–1735 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10859378</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton, D. R., Williamson, R. A. &amp; Parren, P. W. Antibody and virus: Binding and neutralization. Virology270, 1–3 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10772973</ArticleId></ArticleIdList></Reference><Reference><Citation>He, Q. et al. An updated atlas of antibody evasion by sars-cov-2 omicron sub-variants including bq. 1.1 and xbb. Cell Rep.4, 1 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10027947</ArticleId><ArticleId IdType="pubmed">37019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez, T. R., Martin, K. P., Barnes, J. E., Patel, J. S. &amp; Ytreberg, F. M. Assessment of software methods for estimating protein-protein relative binding affinities. PLoS ONE15, e0240573 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751979</ArticleId><ArticleId IdType="pubmed">33347442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapozhnikov, Y., Patel, J. S., Ytreberg, F. M. &amp; Miller, C. R. Statistical modeling to quantify the uncertainty of foldx-predicted protein folding and binding stability. BMC Bioinform.24, 1–18 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10642056</ArticleId><ArticleId IdType="pubmed">37953256</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, C. R. et al. Initiating a watch list for ebola virus antibody escape mutations. PeerJ4, e1674 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768679</ArticleId><ArticleId IdType="pubmed">26925318</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach, S. S., Hull, M. A., Ytreberg, F. M., Patel, J. S. &amp; Miura, T. A. Molecular modeling predicts novel antibody escape mutations in the respiratory syncytial virus fusion glycoprotein. Virol. J.96, e00353-22 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278155</ArticleId><ArticleId IdType="pubmed">35678603</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymkowitz, J. et al. The foldx web server: An online force field. Nucleic Acids Res.33, W382–W388 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160148</ArticleId><ArticleId IdType="pubmed">15980494</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat covid-19. Science371, 850–854 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963219</ArticleId><ArticleId IdType="pubmed">33495308</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney, A. J. et al. Mapping mutations to the sars-cov-2 rbd that escape binding by different classes of antibodies. Nat. Commun.12, 4196 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8263750</ArticleId><ArticleId IdType="pubmed">34234131</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N. et al. Sars-cov-2 rbd antibodies that maximize breadth and resistance to escape. Nature597, 97–102 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9282883</ArticleId><ArticleId IdType="pubmed">34261126</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N., Greaney, A. J., Dingens, A. S. &amp; Bloom, J. D. Complete map of sars-cov-2 rbd mutations that escape the monoclonal antibody ly-cov555 and its cocktail with ly-cov016. Cell Rep.2, 1 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N. et al. Deep mutational scans for ace2 binding, rbd expression, and antibody escape in the sars-cov-2 omicron ba. 1 and ba. 2 receptor-binding domains. PLoS Pathog.18, e1010951 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9674177</ArticleId><ArticleId IdType="pubmed">36399443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature597, 103–108 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9341430</ArticleId><ArticleId IdType="pubmed">34280951</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastman, P. et al. Openmm 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Comput. Biol.13, e1005659 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5549999</ArticleId><ArticleId IdType="pubmed">28746339</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Spoel, D. et al. Gromacs: Fast, flexible, and free. J. Comput. Chem.26, 1701–1718 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16211538</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer, P., Hess, B. &amp; Lindahl, E. Gromacs 2022.5 Source Code. 10.5281/zenodo.7586780 (2023).</Citation></Reference><Reference><Citation>Huang, J. &amp; MacKerell, A. D. Jr. Charmm36 all-atom additive protein force field: Validation based on comparison to nmr data. J. Comput. Chem.34, 2135–2145 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800559</ArticleId><ArticleId IdType="pubmed">23832629</ArticleId></ArticleIdList></Reference><Reference><Citation>Price, D. J. &amp; Brooks, C. L. III. A modified tip3p water potential for simulation with ewald summation. Chem. Phys.121, 10096–10103 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15549884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauchy, A. et al. Méthode générale pour la résolution des systemes d’équations simultanées. Comp. Rend. Sci. Paris25, 536–538 (1847).</Citation></Reference><Reference><Citation>Hess, B., Bekker, H., Berendsen, H. J. &amp; Fraaije, J. G. Lincs: A linear constraint solver for molecular simulations. J. Comput. Chem.18, 1463–1472 (1997).</Citation></Reference><Reference><Citation>Bussi, G., Donadio, D. &amp; Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys.126, 1 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17212484</ArticleId></ArticleIdList></Reference><Reference><Citation>Daura, X. et al. Peptide folding: When simulation meets experiment. Angew. Chem. Int. Ed.38, 236–240 (1999).</Citation></Reference><Reference><Citation>Guerois, R., Nielsen, J. E. &amp; Serrano, L. Predicting changes in the stability of proteins and protein complexes: A study of more than 1000 mutations. J. Mol. Biol.320, 369–387 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12079393</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutelle, S. et al. The hill equation: A review of its capabilities in pharmacological modelling. Fundam. Clin. Pharmacol.22, 633–648 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19049668</ArticleId></ArticleIdList></Reference><Reference><Citation>Gesztelyi, R. et al. The hill equation and the origin of quantitative pharmacology. Arch. Hist. Exact Sci.66, 427–438 (2012).</Citation></Reference><Reference><Citation>Bachmann, M. F., Mohsen, M. O. &amp; Speiser, D. E. Increased receptor affinity of sars-cov-2: A new immune escape mechanism. NPJ Vaccines7, 56 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132958</ArticleId><ArticleId IdType="pubmed">35614112</ArticleId></ArticleIdList></Reference><Reference><Citation>Reverberi, R. &amp; Reverberi, L. Factors affecting the antigen-antibody reaction. Blood Transf.5, 227 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581910</ArticleId><ArticleId IdType="pubmed">19204779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sela-Culang, I., Kunik, V. &amp; Ofran, Y. The structural basis of antibody-antigen recognition. Front. Immunol.4, 302 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792396</ArticleId><ArticleId IdType="pubmed">24115948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoare, S. R., Fleck, B. A., Williams, J. P. &amp; Grigoriadis, D. E. The importance of target binding kinetics for measuring target binding affinity in drug discovery: A case study from a crf1 receptor antagonist program. Drug Discov. Today25, 7–14 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31557449</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, D., Rawat, P., Greiff, V., Janakiraman, V. &amp; Gromiha, M. M. Predicting the immune escape of sars-cov-2 neutralizing antibodies upon mutation. Biochim. Biophys. Acta1870, 166959 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37967796</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, T. &amp; Rehmsmeier, M. The precision-recall plot is more informative than the roc plot when evaluating binary classifiers on imbalanced datasets. PLoS ONE10, e0118432 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4349800</ArticleId><ArticleId IdType="pubmed">25738806</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, C. R., Lee, K. H., Wichman, H. A. &amp; Ytreberg, F. M. Changing folding and binding stability in a viral coat protein: A comparison between substitutions accessible through mutation and those fixed by natural selection. PLoS ONE9, e112988 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236103</ArticleId><ArticleId IdType="pubmed">25405628</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino, M. et al. Analysis and interpretation of the impact of missense variants in cancer. Int. J. Mol. Sci.22, 5416 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196604</ArticleId><ArticleId IdType="pubmed">34063805</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey, W. T. et al. Sars-cov-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol.19, 409–424 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen, N. J. &amp; Kepp, K. P. Accurate stabilities of laccase mutants predicted with a modified foldx protocol. J. Chem. Inf. Model.52, 3028–3042 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23102044</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom, J. D. &amp; Glassman, M. J. Inferring stabilizing mutations from protein phylogenies: Application to influenza hemagglutinin. PLoS Comput. Biol.5, e1000349 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664478</ArticleId><ArticleId IdType="pubmed">19381264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandiana, R., Barletta, G. P., Soler, M. A., Fortuna, S. &amp; Rocchia, W. Computational mutagenesis of antibody fragments: Disentangling side chains from [Image: see text] g predictions. JCTC20, 2630–2642 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">38445482</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums, D. V. The xbb. 1.5 (‘kraken’) subvariant of omicron sars-cov-2 and its rapid global spread. Med. Sci. Monit.29, e939580 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9901170</ArticleId><ArticleId IdType="pubmed">36722047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, E. Prediction of antibody binding to sars-cov-2 rbds. Bioinform. Adv.3, 103 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9868522</ArticleId><ArticleId IdType="pubmed">36698760</ArticleId></ArticleIdList></Reference><Reference><Citation>Decherchi, S. &amp; Cavalli, A. Thermodynamics and kinetics of drug-target binding by molecular simulation. Chem. Rev.120, 12788–12833 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011912</ArticleId><ArticleId IdType="pubmed">33006893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, F. et al. Engineering sars-cov-2 neutralizing antibodies for increased potency and reduced viral escape pathways. Iscience25, 1 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9367177</ArticleId><ArticleId IdType="pubmed">35971553</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, H., Lan, P. D., Nissley, D. A., O’Brien, E. P. &amp; Li, M. S. Cocktail of regn antibodies binds more strongly to sars-cov-2 than its components, but the omicron variant reduces its neutralizing ability. J. Phys. Chem. B126, 2812–2823 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016775</ArticleId><ArticleId IdType="pubmed">35403431</ArticleId></ArticleIdList></Reference><Reference><Citation>Idaho C3+3 Collaboration. Falcon: High Performance Supercomputer (University of Idaho, 2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>